Clareo Health | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of adenocarcinoma of the prostate.
Metastatic prostate cancer (positive bone scan or measurable disease).
Progressive disease after androgen deprivation.
No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer).
You may not be if
Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for greater than or equal to 5 years.
Previous occurrence of autoimmune disease.
Active infection requiring therapy including HIV or chronic hepatitis.
